ALKSHealthcare · Drug Manufacturers - Specialty & GenericThe 18 Wall Street analysts covering Alkermes Plc hold a median 12-month price target of $58 — +23.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 2 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Alkermes Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (22): The company has been issuing shares or taking on financing, diluting existing holders.
Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ALKS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +23.7% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 July 2026 | Baird | Maintains | Outperform | $48 → $58 |
| 29 July 2026 | JP Morgan | Maintains | Neutral | $60 → $61 |
| 28 July 2026 | Piper Sandler | Reiterates | Overweight | $43 → $65 |
| 20 July 2026 | Stifel | Reiterates | Buy | $45 → $63 |
| 20 July 2026 | Stifel | Reiterates | Buy | — |
| 13 July 2026 | JP Morgan | Reinstates | Neutral | $60 |
| 13 July 2026 | Needham | Maintains | Buy | $61 → $62 |
| 13 July 2026 | Needham | Maintains | Buy | — |
| 2 July 2026 | Mizuho | Maintains | Outperform | — |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | — |
| 29 June 2026 | Wells Fargo | Maintains | Overweight | — |
| 24 June 2026 | Needham | Maintains | Buy | — |
| 22 June 2026 | TD Cowen | Maintains | Buy | — |
| 18 June 2026 | Needham | Maintains | Buy | — |
| 9 June 2026 | RBC Capital | Maintains | Outperform | — |
| 13 May 2026 | Baird | Maintains | Outperform | — |
| 6 May 2026 | Needham | Maintains | Buy | — |
| 6 May 2026 | UBS | Maintains | Buy | — |
| 6 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 9 Apr 2026 | B of A Securities | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALKS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, Alkermes Plc returned +56.3% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 6% of US stocks
Cheaper than 26% of US stocks
Cheaper than 24% of US stocks
Cheaper than 9% of US stocks
Higher than 76% of US stocks
Higher than 2% of US stocks
Higher than 93% of US stocks
Higher than 73% of US stocks
Higher than 57% of US stocks
Higher than 52% of US stocks
Higher than 72% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alkermes Plc has a market value of $7.9B and an enterprise value of $8.8B.
Revenue in the twelve months to 31 Mar 2026: $1.6B. The latest quarter grew 27.0% year on year.
Net income over the same four quarters: $152.7M, a 9.8% net margin.
Diluted earnings per share, trailing twelve months: $0.90.
Free cash flow in the twelve months to 31 Mar 2026: $221.8M, after $35.0M of capital spending.
Alkermes Plc spent $27.7M on share buybacks in the twelve months to 31 Mar 2026.
Trailing P/E: 124.2×; forward P/E: 25.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Alkermes Plc employs 2,050 people — $762K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alkermes Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Alkermes' Chief Commercial Officer sold 7,576 shares, generating approximately $373,000 in proceeds. The transaction reduced the executive's direct equity holdings by 7%.
Why it matters — ALKS watchers would care because insider selling can be a signal about management sentiment regarding the company's stock.
Alkermes reported its quarterly earnings 30 days ago, and its stock has risen 1.7% since that report. The article examines what may come next for the company's shares following the earnings announcement.
Why it matters — The piece provides context on how Alkermes shares have performed since its latest earnings report, which is relevant for investors tracking the company's recent financial results.
Alkermes announced that data from its Vibrance-1 phase 2 study of alixorexton, an investigational oral selective orexin 2 receptor agonist, in adults with narcolepsy type 1 were published in The Lancet Neurology. The results were described as positive.
Why it matters — This peer-reviewed publication of positive phase 2 data supports the advancement of alixorexton, a key pipeline candidate for Alkermes in narcolepsy and related sleep disorders.
Alkermes (ALKS) shares have risen approximately 27% over the past three months, gaining 26.5% during that period. The advance is attributed to strong proprietary product sales and progress in its pipeline as the company looks toward the rest of 2026.
Why it matters — For ALKS watchers, the article highlights that momentum from proprietary product sales and pipeline advancement is underpinning the stock's recent gains.
Alkermes plc published the transcript of its Q2 2026 earnings call, covering the company's quarterly financial discussion with analysts.
Why it matters — ALKS watchers monitor earnings call transcripts for management's commentary on financial performance, strategy, and outlook.
The 18 Wall Street analysts covering Alkermes Plc have a median 12-month price target of $58, with estimates ranging from $38 to $72. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering Alkermes Plc, 14 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Alkermes Plc 61 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, Alkermes Plc ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +23.7% from the last close, and Ticker Nerd's factor model ranks Alkermes Plc 61 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alkermes Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALKS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $72 over the next 12 months.
Alkermes Plc returned +56.3% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Alkermes plc is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medicines for central nervous system disorders and other serious conditions. Its current portfolio includes treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence, and narcolepsy-related symptoms, with products such as ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ.
The most recent item we track (The Motley Fool, 29 Aug 2026): "Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000". Alkermes' Chief Commercial Officer sold 7,576 shares, generating approximately $373,000 in proceeds. The transaction reduced the executive's direct equity holdings by 7%.
Alkermes plc is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medicines for central nervous system disorders and other serious conditions. Its current portfolio includes treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence, and narcolepsy-related symptoms, with products such as ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ. The company works across research, clinical development, and product commercialization, using its drug formulation and delivery capabilities to support therapies designed for complex and chronic illnesses. Alkermes plc serves patients, healthcare providers, and healthcare systems in the United States, Ireland, and international markets. Founded in 1987 and headquartered in Dublin, Ireland, the company holds a notable position in the neuroscience-focused biopharmaceutical sector.
CEO Mr. Blair C. Jackson · 2,050 employees · Ireland · https://www.alkermes.com
